We examined whether MA- or LAM-treated CD141+ DCs loaded with tumor antigen can gain the ability to prime naïve autologous CD8+ T cells into tumor-specific CTLs in a class I MHC-restricted manner by cross-reactivity. The gene discussed is THBD; the disease is neoplasm.